1. Introduction {#sec1}
===============

The occurrence and development of malignant tumors are mainly caused by the activation of oncogene and inactivation of tumor suppressor genes. In colorectal cancer (CRC), tumor suppressor genes are significantly inhibited with the progression of cancer. Screening genes with the function of inhibiting tumor growth in advanced CRC is helpful to find the way of suppressing the progression and metastasis of tumor. A gene is a locus (or region) of DNA which is made up of nucleotides and produces biological function through gene expression and protein coding. In the progression of cancer, the expression of oncogenes is enhanced, while the expression of tumor suppressor gene is inhibited. Methylation modification is essential for gene expression. DNA methylation can shut down the activity of certain genes, while demethylation promotes the activity of genes. Hence, the change of methylation levels is a critical index in the process of screening tumor suppressor genes. In advanced CRC, tumor cell can metastasize to lymph nodes and even distant organ. In this stage, the activity of tumor suppressor gene is significantly inhibited. Therefore, the activation of tumor suppressor genes may be the potential way for the treatment of CRC. This study analyzed genes expression and methylation levels in the different stage of CRC to find out genes with decreased expressions and increased methylation levels in advanced CRC. By comparing methylation levels in different stage, gene with continuously upregulation methylation levels in the progression of CRC was screened. After screening,*MBD1* may be a tumor suppressor gene in advanced CRC. In order to figure out the potential mechanism of*MBD1* in the process of tumor inhibition, this study further screened genes related to*MBD1*high expression in CRC gene expression profile.

2. Methods and Materials {#sec2}
========================

2.1. Data Source {#sec2.1}
----------------

DNA methylation data of CRC was from Level 3 Cancer Genome Altas (TCGA) \[[@B1]\], with Illumina Human Methylation 27 as the data chip platform, including 37 cases of normal CRC data and 166 cases of CRC data. The 166 cases of CRC data included 32 cases of stage I data, 64 of stage II data, 45 of stage III data, 24 of stage IV data, and 1 case with unclear stage. This study mainly analyzed the methylation data of the 165 CRC cases.

CRC gene expression profile data were taken from TCGA, with Agilent G4502A as the data chip platform, including 174 cases of expression profile data (19 cases of normal CRC and 155 cases of CRC) ([Table 1](#tab1){ref-type="table"}).

2.2. Gene Screening with Differential Methylation and Expression {#sec2.2}
----------------------------------------------------------------

According to AJCC stage, early CRC data (stage I and stage II) and metastatic CRC data (stage III and stage IV) were compared with 37 cases of normal CRC data to screen genes with differential methylation level. In the analysis of gene expression, based on the 155 cases of CRC expression profile data, early CRC data (stage I data and stage II) and metastatic CRC data (stage III and stage IV) were compared with 19 cases of normal CRC data to screen genes with differential expression. Unpaired *t*-test was used for gene screening. Bonferroni FWER \[[@B2]\] was performed for adjusting *p* value to control false discovery rate (FDR). *p* value less than 0.05 was considered significant difference.

CRC methylation data were divided into four groups (I, II, III, and IV stage) in order to screen genes with continuous increase or decrease of methylation level at the four stages. Multiple comparisons were performed for differential gene expression screening followed by paired comparison (stage II versus stage I; stage III versus stage II; stage IV versus stage III) by using One-way ANOVA. The folder change of differential gene was 1 time. Bonferroni FWER was performed to adjust *p* value. *p* value less than 0.05 was considered significant difference. The intersection was taken from the three paired differential genes. Based on the progression of CRC, genes with continuous increase or decrease of methylation level at the four stages were selected.

Bonferroni FWER was a step-wise process, in an individual correction way for each *p* value and multiplying each gene\'s *p* value by its number on gene lists. It shows significance if the corrected *p* value was less than the error ratio. The corrected *p* value equals the multiplication of *p* value by gene number and is less than 0.05. Therefore, if 1000 genes were tested each time, single *p* value accepted was 0.00005 at most, thus making correction strict. We did so by using Bonferroni FWER to correct *p* value to ensure reliability of the screened out difference genes, especially when colorectal cancer tissues had less difference.

2.3. Regulation Mechanism of*MBD1* in CRC {#sec2.3}
-----------------------------------------

Expression profile data GSE39582 (including 566 cases of CRC tissues) taken from Gene Expression Omnibus (GEO) \[[@B3]\] were used to analyze the potential mechanism of*MBD1* in CRC. To clarify the effect of high and low expression of*MBD1* on CRC expression profile, 566 cases of expression profile data were divided into high and low groups according to the expression of*MBD1* in CRC: expression of*MBD1* was ordered from high to low and divided into two groups (*MBD1* high expression*and MBD1* low expression) with 283 cases in each group; GSEA \[[@B4], [@B5]\] was used for enrichment analysis between the two group based on chromosome location (gene set, version V5.1).

3. Results {#sec3}
==========

3.1. Screening Results of Tumor Suppressor Gene {#sec3.1}
-----------------------------------------------

To screen genes with the function of tumor inhibition in advanced CRC, only genes with downregulated mRNA expression and upregulated methylation level in metastatic CRC were selected. Based on the data from TCGA database, early CRC data (stage I data and stage II) and metastatic CRC data (stage III and stage IV) were compared with normal CRC data and finally 1470 genes with upregulated methylation level, 2677 genes with downregulated methylation level, 1984 genes with upregulated expression, and 3255 genes with downregulated expression were obtained in early CRC. There were 1164 genes with upregulated methylation level, 2569 genes with downregulated methylation level, 1882 genes with upregulated expression, and 3143 genes with downregulated expression obtained in advanced CRC.

The intersection analysis was performed based on the differential expression genes and differential methylation genes and divided into four groups: (1) intersection was obtained from genes with upregulated methylation level in early stage and in advanced stage; 355 specific genes with upregulated methylation in early stage; and 49 specific genes with upregulated methylation in advanced stage and 1115 common genes were collected; (2) intersection was obtained from genes with downregulated methylation level in early stage and in advanced stage; 522 specific genes with downregulated methylation in early stage; and 414 specific genes with downregulated methylation in advanced stage and 2155 common genes were collected; (3) intersection was obtained from genes with upregulated gene expression in early stage and in advanced stage; 315 specific genes with upregulated expression in early stage, and 213 specific genes with upregulated expression in advanced stage and 1669 common genes were collected; (4) intersection was obtained from genes with downregulated gene expression in early stage and in advanced stage; 428 specific genes with downregulated expression in early stage, and 316 specific genes with downregulated expression in advanced stage and 2827 common genes were collected.

Intersection was performed in genes with upregulated methylation and downregulated gene expression in early stage, and 15 genes were obtained. Intersection was performed in genes with downregulated methylation and upregulated expression in early stage, and 7 genes were obtained. Intersection was performed in genes with downregulated methylation and upregulated expression in advanced stage, and 8 genes were obtained. Intersection was performed in genes with upregulated methylation and downregulated expression in advanced stage, and 3 genes were obtained.

Upregulation of gene expression can promote the performance of gene function, while upregulation of methylation can inhibit gene function. Hence, only the 15 genes with upregulated methylation and downregulated expression in early stage might be the tumor suppressor genes. The 7 genes with downregulated methylation and upregulated expression in early stage might be the cancer-promoting genes. The 8 genes with downregulated methylation and upregulated expression in advanced stage might be the cancer-promoting genes. The 3 genes with upregulated methylation and downregulated expression in advanced stage might be the tumor suppressor genes. From the above results, we found that tumor suppressor gene was more while cancer-promoting gene was less in early stage. In advanced stage, cancer-promoting gene was more while tumor suppressor gene was less.

From the above analysis, we only found 3 genes with upregulated methylation and downregulated gene expression in advanced CRC. In order to screen genes with sustained change of methylation in the four stages of CRC, we compared genes with differential methylation in three paired groups: stage II versus stage I, stage III versus stage II and stage IV versus stage III and obtained the intersection. A total of 163 genes with sustained increasing methylation and 222 genes with sustained decreasing methylation were screened in I, II, III, and IV stages of CRC. Intersection was obtained among the 163 genes with increased methylation in CRC and 3 genes with upregulated methylation and downregulated gene expression in advanced CRC, and finally*MBD1* was screened ([Figure 1](#fig1){ref-type="fig"}).

3.2. Survival Analysis of*MBD1* in CRC {#sec3.2}
--------------------------------------

*MBD1* had upregulated methylation level and downregulated gene expression in advanced CRC and had sustained increasing methylation in the four stages of CRC. Hence,*MBD1* might be a tumor suppressor gene in advanced CRC. For further confirmation, expression profile data GSE17536 taken from GEO database was used for survival analysis of*MBD1*. GSE17536 data includes 177 CRC tissues with determined survival time, with Affymetrix Human Genome U133 Plus 2.0 Array as the chip platform \[[@B6]\]. We extracted 177 expression values of*MBD1*, ordered and divided into*MBD1* high-expression group and*MBD1* low-expression group. Each group included 88 cases of data, with the median data (1 case) being deleted. Kaplan-Meier \[[@B7]\] was used to analyze the survival rate of the two groups with the survival curve drawn ([Figure 2](#fig2){ref-type="fig"}). The results showed that, with the change of*MBD1* expression, the difference of survival rate was significant (*p* = 0.0227). Patients with high-expression*MBD1* had higher survival rate than patients with low-expression*MBD1*.

3.3. Regulation Mechanism of*MBD1* in CRC {#sec3.3}
-----------------------------------------

In order to further confirm the molecular mechanism of*MBD1* in CRC, expression profile data from 566 CRC cases at different stages were divided in the*MBD1* high-expression group and*MBD1* low-expression group and GSEA enrichment analysis was performed based on chromosome location. The results revealed that two gene sets with high enrichment in the*MBD1* high-expression group were located in chromosomes 17P13 (*p* = 0.002) and 17P12 (*p* = 0.002) ([Figure 3](#fig3){ref-type="fig"}). The expressions of the two gene set were upregulated in the*MBD1* high-expression group, suggesting that 17P13 and 17P12 might be the chromosome zone where*MBD1* worked. A total of 89 genes contributed to the enrichment of 17P13 gene set and 12 genes contributed to the enrichment of 17P12 gene set. A total of 1217 known tumor suppressor genes was searched from the tumor suppressor gene database (TSGene 2.0) \[[@B8], [@B9]\]. Intersection was performed among the 1217 genes and previously mentioned 89 genes, and 8 tumor suppressor genes (*HIC1, VPS53, RPA1, ALOX15B, TP53, PFN1, MYBBP1A*, and*GABARAP*) were obtained. No intersection was found among the 1217 genes and previously mentioned 12 genes. Because of all the 8 genes located 17P13 zone, a total of 89 genes in the region of 17P13 were performed through CYTOBAND database of DAVID \[[@B10], [@B11]\] and 17P13.3 and 17P13.1 had higher enrichment. 17P13.3 enrichment included 22 genes, including 5 tumor suppressor genes (*HIC1, VPS53, RPA1, PFN1*, and*MYBBP1A*). 17P13.1 enrichment included 27 genes, including 3 tumor suppressor genes (*ALOX15B, TP53*, and*GABARAP*). In order to clarify the potential mechanism of the 8 tumor suppressor genes, enrichment analysis of transcription factor binding sites was performed by using TFM-Explorer \[[@B12]\] in 22 genes in 17P13.3 zone and 27 genes in 17P13.1 zone. A total of 29 proteins interacted with*MBD1* after being verified by BioGRID \[[@B13]\] database search. Intersection was obtained based on the 29 genes and the enrichment of transcription factors, SP1, was screened. The binding site of SP1 had higher enrichment in the upstream regulation region of 17P13.3 and 17P13.1 and the upstream regulation region of the 8 tumor suppressor genes all found SP1 binding site. Moreover, SP1 could bind with*MBD1*. Hence,*MBD1* may be a tumor suppressor gene in advanced CRC and affect the development and metastasis of CRC by regulating 8 tumor suppressor genes through binding with SP1 ([Figure 4](#fig4){ref-type="fig"}).

4. Discussion {#sec4}
=============

MBD1, named methyl-CpG binding protein 1, is a transcriptional repressor and belongs to one member of methyl-CpG binding domain (MBD) family. MBD1 can negatively regulate the transcriptional activity of RNA polymerase II promoter and be involved in chromosome silencing dependent by methylation. Hence, MBD1 can regulate both gene expression and methylation level. Previous study reported that the upregulation of*MBD1* enhanced the epithelial mesenchymal transition and invasion of pancreatic cancer cells \[[@B14]\], which suggested that*MBD1* contributed to the tumor growth in pancreatic cancer. Another study reported that deletion of 18q21 chromosome where*MBD1* was located occurred frequently in CRC \[[@B15], [@B16]\], which suggested that genes in 18q21 chromosome zone might inhibit tumor growth in CRC. The deletion of 18q21 chromosome could result in the abnormal activation of cancer genes.*MBD1* might be a tumor suppressor gene for its location. Previous studies demonstrated that the polymorphism of*MBD1* was related to the risk of lung cancer \[[@B17], [@B18]\], which provided evidence that*MBD1* might inhibit tumor growth in lung cancer. Hence,*MBD1* expression may have different biological effect in different cancer. In this study,*MBD1* had upregulated methylation and downregulated gene expression in advanced CRC and also had sustained upregulated methylation in the four stages of CRC, which suggested that*MBD1* was a tumor suppressor gene for advanced CRC. In the study of expression profile of CRC, we found that high expression of*MBD1* was closely related to genes in chromosomes 17P12 and 17P13 and the two chromosome zones included many known tumor suppressor genes, such as*HIC1, VPS53, RPA1, ALOX15B, TP53, PFN1, MYBBP1A*, and*GABARAP*. Many studies have been reported that*TP53* was a tumor suppressor gene. Further study found that the upstream regulation region of the 8 tumor suppressor genes all found SP1 binding site. Moreover, SP1 could bind with*MBD1*. Hence,*MBD1* may be a tumor suppressor gene in advanced CRC and affect the development and metastasis of CRC by regulating 8 tumor suppressor genes through binding with SP1. This study determined that*MBD1* may be a tumor suppressor gene in advanced CRC from the aspect of gene expression and methylation level and speculated that*MBD1* could regulate chromosomes 17P12 and 17P13 zones to further regulate the expressions of tumor suppressor genes. Therefore, the activation of*MBD1* in advanced CRC may inhibit and even reverse the development and metastasis of CRC.
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###### 

The distribution of clinical characteristics of methylation and expression profile in CRC patients.

  Characteristics                       Colorectal cancer   
  ------------------------------------- ------------------- -----
  Sum                                   166                 155
  Gender                                                     
   Male                                 83                  79
   Female                               83                  76
  Age at initial pathologic diagnosis                       
   \<50                                 12                  10
   ≥50                                  154                 145
  Anatomic neoplasm subdivision                              
   Ascending colon                      32                  28
   Cecum                                33                  29
   Descending colon                     6                   6
   Hepatic flexure                      8                   9
   Sigmoid colon                        69                  66
   Splenic flexure                      2                   2
   Transverse colon                     15                  14
  TNM                                                        
   T1 + T2 + T3 + T4                    166                 155
   N1 + N2                              67                  60
   M1                                   24                  23
  AJCC pathologic tumor_stage                                
   Stage I                              32                  29
   Stage II                             64                  63
   Stage III                            45                  39
   Stage IV                             24                  23
  Histologic diagnosis                                       
   Colon adenocarcinoma                 140                 131
   Colon mucinous adenocarcinoma        24                  22
  Family history colorectal cancer                           
   Yes                                  26                  23
   No                                   140                 132
  History of another malignancy                              
   Yes                                  9                   9
   No                                   157                 146
  History colon polyps                                       
   Yes                                  85                  84
   No                                   81                  71
  Tumor status                                               
   Tumor free                           10                  10
   With tumor                           155                 144
  Vascular invasion indicator                                
   Yes                                  37                  34
   No                                   106                 107
  Lymphovascular invasion indicator                          
   Yes                                  87                  78
   No                                   70                  72
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